Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

68.73
Delayed Data
As of Apr 20
 -0.50 / -0.72%
Today’s Change
51.05
Today|||52-Week Range
135.59
+17.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.6B

Company Description

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Contact Information

Intercept Pharmaceuticals, Inc.
10 Hudson Yards
New York New York 10001
P:(646) 747-1000
Investor Relations:

Employees

Shareholders

Mutual fund holders51.00%
Individual stakeholders38.95%
Other institutional24.07%

Top Executives

Mark E. PruzanskiPresident, Chief Executive Officer & Director
Jerome B. DursoChief Operating Officer
Sandip S. KapadiaCFO, Treasurer & Principal Accounting Officer
David A. ShapiroChief Medical Officer
Christian WeyerExecutive Vice President-Research & Development